Abatacept, Infliximab Improved Survival in Adults Hospitalized With COVID-19
Topline results were announced from a phase 3 trial evaluating the efficacy and safety of a single dose of abatacept or infliximab in adults hospitalized with moderate to severe COVID-19....
-
Focus on Infectious Disease3yrThe Phase 3 NIH study assessed the efficacy and safety of a single dose of immune modulators including intravenous abatacept (Orencia) 10 mg/kg compared with placebo and standard of care Show More
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Source : https://www.nejm.org/doi/full/10.1056/NEJMoa2116620
The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown...
Conclusions: A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns. (Funded by AstraZeneca and the U.S. government; PROVENT ClinicalTrials.gov number, NCT04625725. opens in new tab.)
Post-Acute Sequelae of SARS-CoV-2 Infection: A Descriptive Clinical Study
Source : https://neuro.psychiatryonline.org/doi/10.1176/appi.neuropsych.21070193
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in...
Conclusions: These preliminary findings suggest that post-acute sequelae of SARS-CoV-2 vary in frequency and duration with relation to premorbid history and that these conditions affect functional domains and patients’ ability to return to work. Longitudinal research with larger cohorts is needed to characterize PASC and to optimize care,...
Conclusions and Relevance: This cohort study of SARS-CoV-2 exposure in utero found preliminary evidence that maternal SARS-CoV-2 may be associated with neurodevelopmental sequelae in some offspring. Prospective studies with longer follow-up duration will be required to exclude confounding and confirm these associations.
Severity and prognostic factors of SARS-CoV-2-induced pneumonia: the value of clinical and laboratory biomarkers and the A-DROP score
Source : https://www.researchsquare.com/article/rs-1542245/v1
Introduction. Numerous clinical and laboratory scores that include C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase (LDH), interleukin 6 (IL-6), procalcitonin (PCT), blood urea nitrogen (BUN), creatinine levels and oxygenation (PaO2...
Conclusions: Numerous laboratory biomarkers in addition to obesity, dizziness at the time of admission and the history of hypertension may predict the need for ICU admission and ventilation, as well as mortality in COVID-19. Moreover, A-DROP may be a suitable scoring system for the assessment of general health and disease outcome in COVID-19.